Healthcare AI Product Strategy Starts With the Regulatory Boundary
Editorial revision: . Original publication and source dates are retained.
FDA activity around non-device software and clinical decision support makes one product decision unavoidable: define what the software does, who uses it, what evidence they can independently review, and where the function crosses into regulated device territory.
Return to insightsHealthcare AI founders, product leaders, clinical leaders, compliance teams, and investors / 2026-07-19
The strategic question
Can the intended user independently review the basis of the recommendation, and does the software support judgment or make a consequential medical determination?
This is product and operating analysis based on public FDA guidance. It is not legal, regulatory, or clinical advice.
Executive thesis
Product scope determines the evidence burden.
Intended use, user, function, evidence, and consequence should shape the product architecture from the outset. Labels such as copilot or AI assistant do not settle the regulatory boundary. Define each function early so the demonstration, roadmap, commercial claims, validation, human authority, and quality controls describe the same intended product.
Public facts
On July 14, 2026, FDA requested public input on risks, benefits, and patient-safety practices for non-device software functions, including administrative support, records, data display, healthy-lifestyle functions, and certain limited clinical decision support.
FDA's January 2026 final guidance explains the statutory criteria for certain non-device clinical decision support functions and distinguishes them from device software functions.
FDA states that device policies continue to apply to software functions that meet the device definition, including certain functions intended for patients or caregivers.
My assessment
The boundary should be resolved function by function. A single application can contain low-risk administrative workflow, professional decision support, and higher-risk patient-specific functions with different obligations.
Explainability is not merely a model feature. It is a workflow property: the right user must receive enough evidence, context, and time to exercise independent judgment.
Commercial claims can move the boundary. Promising diagnosis, treatment selection, or autonomous action creates a different diligence posture than supporting an administrative or clinician-reviewed task.
Change management matters because the function can drift when a model, prompt, data source, user population, or workflow changes even if the interface looks the same.
Operating model
Underwrite the responsibility the product assumes.
I would make intended use an input to product economics. A change in the decision influenced, the user or the degree of autonomy can change the evidence, assurance and support the business must finance. The commercial team should therefore assess feature expansion with product, clinical and regulatory expertise before selling a broader promise.
The strategic choice is how much responsibility the product can credibly assume. A narrower function with a well-supported workflow can be commercially more durable than a broader function whose evidence and operating obligations exceed the organization’s resources. That is a product-boundary decision, not a recommendation to avoid applicable requirements. The scope should remain consistent across the contract, interface, validation and ongoing release process.
Operating framework
- 01
Write the intended use, user, decision, timing, input data, output, and consequence in plain language.
- 02
Map each function separately because one product can contain administrative, non-device CDS, and device software functions.
- 03
Design evidence visibility so the healthcare professional can understand and independently review the basis where required.
- 04
Align claims, validation, quality management, monitoring, and change control to the highest-risk function.
- 05
Reassess the boundary whenever the model, user, autonomy, output, or clinical context changes.
Metrics that matter
- 01
Functions with documented intended use and owner
- 02
Recommendation traceability to supporting evidence
- 03
Validation performance by user and clinical context
- 04
Override, exception, and adverse-event rates
- 05
Time from model change to controlled release
Buyer implications
Founders should make the intended-use statement a product requirement, not a late legal artifact.
Buyers should diligence each function, evidence path, user role, update process, and escalation model.
Product and clinical teams need one shared release gate for claims, validation, monitoring, and workflow controls.
Management priorities
Create a function-level regulatory and evidence map.
Align website claims, sales language, product requirements, and validation artifacts.
Design independent review into the user workflow where applicable.
Trigger boundary review when intended use, model behavior, user, or autonomy changes.
Red flags
The marketing claim is broader than the documented intended use.
The user cannot inspect the basis of a patient-specific recommendation.
A model update changes clinical behavior without renewed validation and release governance.
CEO and CFO questions
What exact medical or operational decision does each function influence?
Who is the intended user and how much time do they have to review the basis?
Which claims require evidence beyond a technical benchmark?
What change would move this function across the regulatory boundary?
Connect intended use, workflow, evidence, human authority, claims, and release governance before scale.
Map the product boundaryDiscuss the strategic decision